Photo from Aakash Desai/LinkedIn
Sep 16, 2024, 15:57
Aakash Desai: Our latest research at ESMO24 on HER2 Expression across Solid Tumors
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn:
“Excited to present our latest research at ESMO24 on HER2 Expression across Solid Tumors and its Real-World Implications for the Use of fam-trastuzumab deruxtecan-nxki (T-DXd)! ESMO – European Society for Medical Oncology, UAB O’Neal Comprehensive Cancer Center
Our study delves deep into the varying expression of HER2 across different solid tumors and provides valuable insights into the practical use of T-DXd in clinical settings.
Here are some key takeaways:
- Diverse Expression Patterns: HER2 shows a wide range of expression levels across different tumor types, underscoring the complexity and variability in tumor biology.
- Real-World Data: The study highlights the significance of real-world evidence in understanding HER2 expression and tailoring treatment strategies accordingly.”
Source: Aakash Desai/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12